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Abstract
Myeloid dendritic cells (mDC) are lost from blood in individuals with human immunodeficiency virus (HIV) infection but the
mechanism for this loss and its relationship to disease progression are not known. We studied the mDC response in blood
and lymph nodes of simian immunodeficiency virus (SIV)-infected rhesus macaques with different disease outcomes. Early
changes in blood mDC number were inversely correlated with virus load and reflective of eventual disease outcome, as
animals with stable infection that remained disease-free for more than one year had average increases in blood mDC of
200% over preinfection levels at virus set-point, whereas animals that progressed rapidly to AIDS had significant loss of mDC
at this time. Short term antiretroviral therapy (ART) transiently reversed mDC loss in progressor animals, whereas
discontinuation of ART resulted in a 3.5-fold increase in mDC over preinfection levels only in stable animals, approaching 10-
fold in some cases. Progressive SIV infection was associated with increased CCR7 expression on blood mDC and an 8-fold
increase in expression of CCL19 mRNA in lymph nodes, consistent with increased mDC recruitment. Paradoxically, lymph
node mDC did not accumulate in progressive infection but rather died from caspase-8-dependent apoptosis that was
reduced by ART, indicating that increased recruitment is offset by increased death. Lymph node mDC from both stable and
progressor animals remained responsive to exogenous stimulation with a TLR7/8 agonist. These data suggest that mDC are
mobilized in SIV infection but that an increase in the CCR7-CCL19 chemokine axis associated with high virus burden in
progressive infection promotes exodus of activated mDC from blood into lymph nodes where they die from apoptosis. We
suggest that inflamed lymph nodes serve as a sink for mDC through recruitment, activation and death that contributes to
AIDS pathogenesis.
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Introduction
Myeloid dendritic cells (mDC) are professional antigen-present-
ing cells that are critical for the induction of acquired immune
responses to pathogens [1]. Depletion of mDC from blood in
human immunodeficiency virus (HIV) infection has been well
described and shown to be inversely correlated with virus load and
absent from long-term non-progressors, suggesting a relationship
between mDC and disease control [2–8]. A proposed mechanism to
account for mDC loss from blood is their activation and subsequent
recruitment to inflamed lymph nodes [9]. Increased expression of
costimulatory molecules on blood mDC indicative of activation has
been reported in HIV-infected individuals [3,5,10], as has
accumulation of mDC in peripheral lymph nodes during acute
infection [11]. However, findings relating to mDC in lymph nodes
during chronic HIV infection are inconsistent, with both accumu-
lation [12,13] and substantial loss of mDC [14] being reported.
mDC are depleted from both blood and lymph nodes of simian
immunodeficiency virus (SIV)-infected rhesus macaques during
AIDS [15] but data are lacking from earlier stages of infection. Few
studies have evaluated mDC dynamics in both blood and lymph
node in the same individuals [12,15] and no longitudinal studies of
mDC kinetics in both compartments have been reported. As such,
the relationship between mDC loss and recruitment in infection
remains ill-defined, and whether differences in mDC dynamics
predict disease outcome is not known.
The impact of antiretroviral therapy (ART) on mDC loss and
recovery in HIV infection is also unclear, as several studies
indicate that ART is not effective at increasing blood mDC
[6,7,16] while others suggest that ART significantly restores blood
mDC numbers [3,8,17,18]. ART rapidly resolves immune
activation in lymphoid tissues [19] and may have beneficial effects
on lymph node mDC activation and function [13], although this
has not been well characterized.
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In the present study we followed the mDC response in blood
and lymph nodes over time in two cohorts of SIV-infected animals
that received ART and adenovirus (Ad)-based immunotherapy
with different disease outcomes. We find that loss of blood mDC at
virus set-point is predictive of disease progression, whereas an
increase in blood mDC is predictive of long-term absence of
disease, and that even relatively short periods of ART are
beneficial to mDC homeostasis. In animals that progress to AIDS
the early loss of mDC from blood is associated with evidence of
increased CCR7-CCL19-mediated recruitment to lymph nodes
and increased apoptosis within these tissues.
Results
Disease progression is independent of Ad-based
immunotherapy
Animals in this study were enrolled in an immunotherapy
protocol using Ad-based vectors the majority of which has been
previously described [20]. Animals were infected with the
pathogenic isolate SIVmac251 by intravenous inoculation and
received ART consisting of a combination of two reverse
transcriptase inhibitors, 9-[2-(phosphonyl-methoxy)propyl]ade-
nine (PMPA) and 29-deoxy-5-fluoro-39-thia-cytidine (FTC), from
weeks 12 to 24 and weeks 32 to 44, depending on survival.
Immunotherapy consisted of priming with Ad serotype 5 (Ad5)-
based vectors expressing SIV Gag, Env and Nef with or without
IL-15 at weeks 16 and 22 followed by boosting with Ad35-based
vectors expressing the same transgenes at weeks 36 and 42.
Control-treated animals were given the same regimen of Ad5-y5
and Ad35-y5 vectors that lacked transgenes [20]. Ad-based
immunotherapy boosted T cell responses to SIV but had no effect
on virus load, progression to disease or survival [20](and data not
shown). However, when analyzed independent of immunotherapy,
animals in the cohort could be readily separated into two groups
based on disease progression, with one group remaining healthy
until elective sacrifice at a mean of 60 weeks post infection (n = 11,
‘stable’ group), and the other succumbing to AIDS with a mean
survival time of 32 weeks (n = 10, ‘progressor’ group, Table 1).
AIDS was defined clinically by lymphadenopathy, persistent
weight loss and anorexia, with or without opportunistic infections
[15]. Equal numbers of animals in the stable and progressor
groups received Ad-based immunotherapy with the remainder
receiving control vectors or no treatment, confirming the lack of
association between immunotherapy and disease outcome
(Table 1). The MHC class I molecule Mamu-A*01 was expressed
by 3/11 and 0/10 animals in the stable and progressor groups,
respectively, consistent with an association of this molecule with
control of SIV infection (Table 1) [21].
Peak plasma virus loads in stable and progressor animals at 2
weeks post infection were similar at around 26107 RNA copies/
ml plasma; however virus loads began to diverge by week 4 and at
virus set point virus loads differed by ,1 log between groups
(Table 1 and Figure 1). Survival time was inversely correlated with
virus load at set-point (Table 1 and Figure 1B), consistent with
previous reports [22,23]. ART beginning at week 12 had parallel
although modest effects on virus load in both groups, with an
immediate decrease of ,1.5 logs that fluctuated over the course of
therapy (Figure 1). Virus load persisted at ,0.5 logs below set-
point levels after discontinuation of ART and then decreased by
,1.5 logs with initiation of the second cycle of ART at week 32,
again with fluctuations over the course of therapy (Figure 1). Only
animals in the stable group survived beyond the second cycle of
ART and in these animals virus load remained at ,1.5 logs below
set-point until sacrifice (Table 1 and Figure 1). These data show
that disease progression and survival in this cohort of animals
correlated with virus load at set-point prior to initiation of ART
and not with Ad-based immunotherapy, and that ART was
effective at inducing modest but similar decreases in virus load in
both groups.
Disease progression correlates with a divergent mDC
response in SIV-infected macaques
The characteristics of this cohort allowed us to ask whether
differences in eventual disease outcome were reflected in earlier
changes in the mDC response and whether short-term exposure to
ART was beneficial to this response. Blood mDC were identified
in peripheral blood mononuclear cells (PBMC) as CD45+ lineage2
HLA-DR+ CD11c+ cells (Figure 2A) and were enumerated based
on the ratio of mDC to CD4+ T cells [20,24]. Staining of blood
cells with antibody to CD11c was inconsistent in animals R487
(stable group) and M5406 (progressor group) making it difficult to
delineate mDC at all time points (data not shown), and as a result
these animals were not studied further. The median number of
blood mDC in the remaining 19 animals prior to infection was
51 cells/ul with a relatively large range from 16 to 202 cells/ul,
consistent with our previous findings (Figure 2C, D) [24]. Blood
mDC were reduced at 2 weeks post infection relative to baseline
levels when all animals were analyzed together (P= .03), although
when each group was analyzed separately this decrease was not
significant. However, in the post-acute period the mDC response
diverged, as mDC in progressor animals continued to decline to
week 12 when they were significantly reduced in number relative
to preinfection time points. In contrast, mDC in stable animals
significantly increased from weeks 2 to 12 (Figure 2B–D). The
relative change in the number of blood mDC in individual animals
over the first 12 weeks of infection was significant, as mDC
dropped to around 30% of preinfection levels in some progressor
animals (mean for the group 60%) but increased to nearly 500% in
some stable animals (mean for the group 206%) (Figure 2E). This
change was inversely correlated with virus load at week 12 post
infection, revealing a relationship between viral burden and mDC
homeostasis (Figure 2E). Exposure to the first round of ART in
progressor animals resulted in an increase in mDC number from
weeks 12 to 20, when virus load was near its lowest point, and
Author Summary
Myeloid dendritic cells (mDC) are essential innate immune
system cells that are lost from blood in human immuno-
deficiency virus infection through an ill-defined mecha-
nism. We studied the kinetics of the mDC response in
blood and lymph nodes of rhesus macaques infected with
the closely related simian immunodeficiency virus. We
found that differences in the number of blood mDC
correlated with eventual disease outcome, as at virus set-
point mDC were increased in blood in animals remaining
disease free but lost from blood in animals that progressed
rapidly to AIDS. mDC loss was linked to an increase in the
chemokine axis responsible for mDC recruitment to lymph
nodes; however, mDC did not accumulate in tissues but
rather died from apoptosis. Lymph node mDC remained
responsive to stimulation with a TLR7/8 agonist during
infection. Importantly, mDC dysregulation was partially
reversed by antiretroviral therapy. These data indicate
that chronic mDC recruitment, activation and death
within lymph nodes precede development of disease in
SIV infected monkeys and may play a role in AIDS
pathogenesis.
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appeared to stabilize the number of blood mDC in the stable
group (Figure 2B–D). However, after ART was discontinued at
week 24 the number of mDC in stable but not progressor animals
rose markedly reaching a mean increase of 3.5 fold over baseline
at week 32, with individual increases approaching 10-fold in some
animals (Figure 2B–D). The magnitude of the mDC response after
ART was not influenced by the vaccination regimen received
during ART, as a comparison of mean mDC counts for all animals
from weeks 28 to 32 (the period of greatest response) based on the
type of immunotherapy received revealed no statistically signifi-
cant differences (data not shown, Kruskal-Wallis test, P= 0.3).
Initiation of the second round of ART again reduced mDC
number in the majority of stable animals, concurrent with the
reduction in virus load, after which the number of mDC remained
relatively constant (Figure 2B, D). The divergent mDC response
contrasted with changes in CD4+ T cells, which did not statistically
differ between groups at any time before or after infection
(Figure 2F). These data indicate that differences in eventual disease
outcome in SIV infection are reflected by differences in the blood
mDC response that are apparent relatively early in infection. They
also indicate that short-term ART may be effective at transiently
restoring blood mDC in animals with the most severe disease.
Blood mDC are rapidly and differentially activated in SIV
infection
We next asked whether differences in disease progression were
reflected in earlier differences in activation of circulating mDC in
SIV-infected macaques. For these and subsequent analyses we
focused on the first 32 weeks of infection incorporating one 12-
week cycle of ART and one 8-week period of treatment
interruption, as after this time the number of animals surviving
in the progressor group rapidly diminished (Table 1). Expression
of the costimulatory molecules CD80 and CD86 was markedly
increased in all animals at 2 weeks post infection indicative of
rapid mDC activation (Figure 3A–D). However, by 12 weeks post
infection differences in mDC activation were evident between
groups particularly with respect to the chemokine receptor CCR7,
which was expressed by a significantly greater proportion of mDC
in animals that progressed to AIDS relative to animals with stable
infection (Figure 3A). A majority of CCR7+ mDC in progressor
Table 1. Characteristics of animal cohort.
Animal ID Mamu type* Immunotherapy"
Set point virus load
(RNA copies/mL){
Time of sacrifice
(weeks PI) {
Disease status at
sacrifice
Stable
R478 A-02/A-08/B-01 Control 3,376,666 56 Healthy
R479 A-01 Ad-SIV 410,333 62 Healthy
R480 A-01 Control 796,666 56 Healthy
R481 ND Ad-SIV/IL-15 189,333 63 Healthy
R484 A-11 Control 2,396,666 62 Healthy
R486 ND Ad-SIV 121,666 62 Healthy
R487 A-01/B-01 Ad-SIV/IL-15 5,833,333 61 Healthy
R489 A-08/B-17 Ad-SIV 1,316,666 62 Healthy
M5306 ND Control 99,000 63 Healthy
M5506 A-08 Ad-SIV/IL-15 3,126,666 56 Healthy
M5606 A-08 Ad-SIV/IL-15 7,300,000 60 Healthy
Mean 2,269,727 60
Progressor
R180 B-01 Ad-SIV 671,000 43 AIDS
R183 B-17 Ad-SIV/IL-15 706,666 43 AIDS
R189 A-02 None 47,500,000 11 AIDS
R477 ND Ad-SIV 14,300,000 32 AIDS
R482 B-01 Control 12,733,333 27 AIDS
R483 ND Ad-SIV 6,700,000 40 AIDS
R485 ND Ad-SIV/IL-15 1,870,000 33 AIDS
R488 B-01 Ad-SIV/IL-15 82,000,000 18 AIDS
M5206 A-02 Ad-SIV 11,333,333 36 AIDS
M5406 ND Control 15,700,000 42 AIDS
Mean 19,351,433 32
P 0.01 ,0.0001
*Expression of known MHC class I Mamu alleles. ND = none of the 8 alleles tested was expressed.
"Immunotherapy was administered at weeks 16 and 22 for Ad5-based vectors and weeks 36 and 42 for Ad35-based vectors. Control = Ad-y5; Ad-SIV = separate vectors
expressing SIV Env, Gag and Nef; Ad-SIV/IL-15 = separate vectors expressing SIV Env, Gag, Nef and IL-15.
{Mean values from week 8–12 post infection.
{Animals in the stable group were electively sacrificed at or after 56 weeks post infection (PI). Animals in the progressor group were sacrificed due to development of
AIDS at the indicated times.
doi:10.1371/journal.ppat.1001235.t001
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animals also expressed CD86 with a smaller proportion expressing
CD80, consistent with activation (Figure 3E). The 12-week course
ART was effective at reducing blood mDC activation, particularly
with respect to CD80, and in animals in the stable group
expression of all markers of activation returned to preinfection
levels during ART (Figure 3A–C). The increase in CD80 at week
32 suggested mDC were again activated during the period of ART
discontinuation, although no increase in CCR7 or CD86
expression was noted at this time (Figure 3A–C). These findings
indicate that during chronic infection animals that progress to
AIDS have increased blood mDC activation relative to animals
with stable infection. They also confirm that ART has the
beneficial effect of reducing mDC activation, consistent with
findings in HIV-infected humans [3,12].
mDC do not accumulate in lymph nodes despite
increased tissue CCL19 expression
The finding that loss of blood mDC in progressor animals
occurs as the proportion of mDC expressing CCR7 increases is
consistent with excessive mDC recruitment to lymph nodes via the
CCR7/CCL19/CCL21 pathway, as has been suggested by in
vitro studies [9]. To examine this potential in vivo, we used flow
cytometry to identify mDC in lymph node cell suspensions taken
prior to infection and at intervals after infection in our two groups
of animals. mDC were defined as lineage2 HLA-DR+ CD11c+
cells (Figure 4A) and enumerated as a proportion of all cells in the
lineage2 HLA-DR+ gate, which we have previously shown to be
an accurate indicator of the absolute number of mDC per unit of
weight [15]. Surprisingly, we found no significant difference in the
number of lymph node mDC as a result of SIV infection regardless
of disease progression, indicating a lack of mDC accumulation
(Figure 4B). However, the phenotype of mDC within lymph nodes
was significantly different as a function of disease, as animals with
stable but not progressive infection had a lower percentage of
mDC expressing CCR7, CD40 and CD86 and reduced mDC
expression of MHC class II at 12 weeks relative to preinfection
time points, reflecting reduced mDC activation (Figure 4C, D). To
address the issue of mDC recruitment further, we next used real
Figure 1. Relationship between virus load and disease progression in SIV infected macaques. (A) Mean virus load in plasma for SIV-
infected animals that progress rapidly to disease (progressor, n = 10) or remain disease free for more than one year (stable, n = 11). *P,0.05, **P,0.01
(week 26). (B) Correlation between survival time and virus load at set-point, taken as the mean virus load from weeks 8 to 12 post infection, for all
animals. Data points for animals R180 and R183, which died at week 43 with very similar virus loads, appear as a single data point. (C, D) Individual
virus load measurements for progressor (C) and stable animals (D). ART = intervals of antiretroviral therapy.
doi:10.1371/journal.ppat.1001235.g001
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time PCR to determine the relative expression of CCR7 ligands in
lymph node tissues. We found that CCL19 but not CCL21 mRNA
was increased 8-fold in lymph nodes at 12 weeks post infection, but
only in animals that progressed to AIDS (Figure 4E). Together
with our findings in blood, these data suggest that mDC are
recruited to lymph nodes in progressive disease via an enhanced
CCR7/CCL19 pathway, but that expanded mDC recruitment
fails to result in mDC accumulation.
Increased mDC apoptosis in lymph nodes during
progressive SIV infection
The lack of mDC accumulation in lymph nodes despite
evidence for enhanced CCR7/CCL19-mediated recruitment in
progressive infection led us to suspect that lymph node mDC were
dying at an increased rate in these tissues. To examine this
possibility we identified live mDC in lymph node cell suspensions
as being lineage2 HLA-DR+ CD11c+ cells that lacked staining
Figure 2. Divergent mDC response in blood correlates with virus load and disease progression. (A) Representative flow cytometry plots
showing the gating strategy used to define CD11c+ mDC within the Lineage2 HLA-DR+ fraction of PBMC. (B) Changes in the absolute number of mDC
in blood over the course of SIV infection in animals with stable (n = 10) and progressive (n = 9) infection. Shown are mean 6 SEM. **P,0.01 between
groups;#P,0.05;##P,0.01 within groups relative to week 12 post infection. (C, D) Individual mDC counts in blood for progressor animals (C, n = 9)
and stable animals (D, n = 10). (E) Correlation between percent change of mDC in blood from week 0 to 12 and virus load at week 12 (n = 18, R189
died at week 11 and is not included). (F) Change in absolute number of CD4 T cells in blood over the course of SIV infection in animals with stable
(n = 10) and progressive (n = 9) infection. Shown are mean 6 SEM. ART = intervals of antiretroviral therapy.
doi:10.1371/journal.ppat.1001235.g002
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with a fixable dead-cell dye, and then identified cells undergoing
early apoptosis within this gate using an antibody to active
caspase-3 (Figure 5A). At week 12 post infection, 15% of lymph
node mDC in animals that eventually progressed to AIDS were
entering apoptosis, representing a 3-fold increase from preinfec-
tion levels, whereas lymph node mDC from animals with stable
infection had no significant change in apoptosis (Figure 5B). ART
given from week 12 to 24 post infection decreased the frequency of
apoptotic mDC in progressor animals, although this did not reach
statistical significance (Figure 5B). To determine whether apoptosis
was mediated by extrinsic or intrinsic pathways we exposed lymph
node cells from progressor animals taken at week 12 post infection
to small molecule inhibitors of caspase-8 or caspase-9, respectively.
The presence of caspase-8 inhibitor Z-IETD-FMK reduced
apoptosis by more than 50% relative to a control peptide whereas
the caspase-9 inhibitor had minimal effect (Figure 5C), suggesting
that cell-extrinsic mediators of apoptosis were predominant.
Consistent with this finding, lymph node mDC taken from
progressor but not stable animals at week 12 post infection showed
a significant increase in the proportion of mDC expressing CD95
relative to preinfection samples (Figure 5D). Together, these data
suggest that increased mDC apoptosis in lymph nodes during
Figure 3. Differential activation of blood mDC in stable and progressive SIV infection. The proportion of blood mDC expressing CCR7 (A),
CD80 (B) and CD86 (C) relative to staining with a control antibody before and at various times after SIV infection. Shown are mean 6 SEM for naı¨ve
(n = 19), progressor (n = 8) and stable animals (n = 10). (D) Representative flow cytometry plots of the gating strategy to identify positive populations.
(E) Flow cytometry plots of CCR7+ mDC from progressor animal R180 at 12 weeks post infection labeled with antibodies to CD80 and CD86. Numbers
represent the percentage of cells that co-express both markers relative to staining with a control antibody. Data are representative of three
experiments on separate animals. *P,0.05, **P,0.01, ***P,0.005 between groups; #P,0.05, ##P,0.01, ###P,0.005 within groups relative to
week 0. ART = interval of antiretroviral therapy.
doi:10.1371/journal.ppat.1001235.g003
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Figure 4. Differential mDC activation and tissue chemokine expression in lymph nodes correlates with disease progression. (A)
Representative flow cytometry plots showing the gating strategy used to define CD11c+ mDC within the Lineage2 HLA-DR+ fraction of peripheral
lymph node cell suspensions. (B) The number of mDC in lymph nodes as a proportion of Lineage2 HLA-DR+ cells at intervals before and after SIV
infection. Shown are mean 6 SEM for naı¨ve (T = 0, n = 18), progressor (n = 7) and stable animals (n = 10). (C) The proportion of lymph node mDC
expressing CCR7, CD40, CD80 and CD86 relative to staining with a control antibody before and 12 weeks after SIV infection (left) and the mean
fluorescence intensity of HLA-DR expression on lymph node mDC at week 12 post infection (right). Shown are mean 6 SEM for naı¨ve (n = 8),
progressor (n = 6) and stable animals (n = 6). (D) Representative flow cytometry plots showing gating strategy to identify positive cell populations. (E)
Dendritic Cell Dysregulation in SIV Infection
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chronic infection in animals that progress to AIDS offsets the
increase in mDC recruitment from blood, resulting in no net
accumulation of mDC.
Evidence of increased responsiveness of lymph node
mDC to stimulation with TLR7/8 agonist during infection
Changes in mDC activation and apoptosis within lymph nodes
during SIV infection could impact the capacity of these cells to
respond to microbial stimuli and subsequently induce adaptive T
cell immune responses. To investigate the functional capacity of
mDC following SIV infection in our two groups of animals we
stimulated lymph node cell suspensions taken at intervals before
and after infection with 3M-007, a small molecule synthetic
agonist of TLR7/8, which, like HIV and SIV RNA, activates
mDC through their engagement of TLR8 [25–27]. We analyzed
mDC for expression of two key immunoregulatory cytokines,
TNF-a and IL-12 (p40/p70). Interestingly, lymph node mDC
taken prior to infection responded relatively poorly to short-term
stimulation with a small proportion of cells producing TNF-a and
IL-12 (Figure 6). In contrast, stimulation of mDC taken at 12
weeks post infection resulted in 20 to 30% of cells producing TNF-
a and a smaller but significant percentage producing IL-12,
representing a 4- to 5-fold increase above preinfection levels
regardless of disease outcome (Figure 6). ART reduced mDC
responsiveness to TLR8 stimulation although this did not reach
statistical significance (Figure 6B). These data indicate that mDC
resident in lymph nodes of SIV-infected rhesus macaques are
functional capable of responding to stimulation, and may even be
hyperresponsive as a consequence of SIV infection.
Discussion
In this study we examined the relationship between mDC
dynamics and disease progression over time in pathogenic SIV
infection of rhesus macaques. We show for the first time that mDC
are preferentially lost from blood in animals that progress to AIDS
but are increased in blood of animals with long-term stable
infection. This divergent mDC response was apparent at virus set-
point, indicating that changes in blood mDC number over the first
3 months of infection are predictive of eventual disease
progression.
mDC are recruited from blood to lymphoid tissues through
upregulation of CCR7, the ligand for chemokines CCL19 and
CCL21 that are expressed in the lymph node paracortex [28]. In
animals with progressive infection, mDC loss from blood was
associated with an increase in the frequency of blood mDC
expressing CCR7 and an increase in expression of CCL19 in
lymph nodes, consistent with increased extravasation to lymph
nodes that exceeded the rate of mDC production from bone
marrow. Expression of CCL19 has been shown previously to be
markedly increased in lymph nodes during the acute phase of SIV
infection [29], and our data suggest that expression in lymph
nodes remains high into chronic infection as a function of virus
load. Indeed, recent studies have shown that increased levels of
CCL19 and CCL21 in blood correlate with higher virus loads and
disease progression in HIV infected humans [30]. In vitro
exposure to CCL19 and CCL21 also promotes an inflammatory
response in PBMC from HIV-infected individuals with high virus
loads [31]. We now provide evidence of a functional link between
CCL19 upregulation in lymph nodes and increased expression of
CCR7 on circulating mDC that promotes mDC recruitment to
lymph nodes in progressive SIV infection. While not examined in
this study, the potential exists for proinflammatory factors to
promote differential emigration of mDC to lymph nodes in
progressive relative to stable SIV infection. In particular,
lipopolysaccharide is increased in the circulation during chronic
HIV and pathogenic SIV infection as a consequence of microbial
translocation through increased gut permeability [32]. Lipopoly-
saccharide activates mDC via engagement of TLR4 [33] and is a
potent activator of DC migration in vivo [34,35].
In contrast to progressive infection, we found that mDC in
animals that controlled SIV infection had significant increases in
blood mDC over time, with increases of up to 5-fold by virus set-
point and nearly 10-fold in some cases at 32 weeks of infection.
Studies in HIV infected individuals have indicated that mDC loss
is inversely proportional to virus load, as we have shown, and is
not observed in long-term non-progressors [2,5,8], but such cross
sectional studies have by design not revealed changes over time.
Increased blood mDC may arise from increased hematopoiesis in
bone marrow in response to inflammatory cytokines such as TNF-
a and IL-1 that are elevated during HIV infection and promote
DC generation [36,37]. The lack of an upregulated CCR7-CCL19
axis in this group would exacerbate the impact of enhanced DC
production and mobilization into blood by limiting mDC exodus
into tissues.
Paradoxically, there was no net increase in mDC within lymph
nodes in monkeys with progressive SIV infection, associated with
an increase in mDC apoptosis, suggesting that increased
recruitment to lymph nodes is offset by increased cell death in
severe infection. mDC apoptosis was caspase-8-dependent and
associated with increased CD95 expression, similar to the findings
for plasmacytoid DC in HIV and SIV infection [38,39], consistent
with a cell-extrinsic mechanism of apoptosis involving CD95
ligation. Apoptosis through virus infection of mDC is unlikely to be
a significant factor, as previous studies indicate that only a minor
fraction of lymph node mDC contain incorporated viral DNA
during peak viremia [38]. HIV and SIV clearly affect mDC in the
absence of productive infection, in particular through interactions
of viral RNA with endosomal TLR8; however this interaction
tends to promote cell survival rather than apoptosis [9,27]. While
the increase in mDC recruitment appears to keep pace with
apoptosis in tissues during the chronic stages of SIV infection
studied here it is clear that mDC are ultimately lost from lymph
nodes as AIDS is established, as previously reported [15]. This
eventual decline may be associated with a similar decline in lymph
node expression of CCL19 in the final stages of disease [29].
Several reports have described the presence of semimature
mDC with reduced expression of costimulatory molecules and/or
CD83 in lymph node and spleen of HIV-infected humans
[11,13,40] and SIV-infected macaques [41,42]. Our data now
suggest that these cells may have a beneficial function in vivo, as
lymph node mDC with significantly lower expression of CCR7
and costimulatory molecules consistent with a semimature state
were present only in animals with long-term stable infection. In
vitro, semimature DC with tolerogenic function are derived from
exposure to immunoregulatory cytokines including IL-10 and
Expression of CCL19 and CCL21 mRNA in lymph node cell suspensions prior to infection (naı¨ve) and at 12 weeks post infection for animals with stable
and progressive infection. mRNA expression levels were calculated using the 22DCT method using [beta]-GUS as the endogenous control. The fold
change in expression was calculated by normalizing to the mean 22DCT of the naı¨ve group. Shown are mean 6 SEM of 4 animals in each group.
*P,0.05, **P,0.01. ART = interval of antiretroviral therapy.
doi:10.1371/journal.ppat.1001235.g004
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transforming growth factor-b [43], however whether these factors
modulate DC maturation and function in progressive versus stable
SIV and HIV infection is not known. Semimature mDC from
HIV-infected lymph nodes have been shown to promote
regulatory T cell function [13]. While we were not able to
examine the effect of these cells on regulatory T cells in this study,
the prevalence of semimature mDC in stable but not progressive
infection might suggest a role for enhanced regulatory T cell
responses in disease control. The role of regulatory T cells in
pathogenic and nonpathogenic SIV infection is currently contro-
versial [44–46], and the interplay between mDC and regulatory T
cells in control and progression to disease deserves attention. In
contrast to stable infection, mDC in lymph nodes of animals with
progressive infection showed essentially no difference in expression
of CCR7 and activation markers relative to naı¨ve animals,
although the proportion of cells expressing these markers was
substantially greater than in blood. It is possible that activated
mDC undergo apoptosis immediately upon entering lymph nodes,
Figure 5. Apoptosis of lymph node mDC increases in progressive but not stable SIV infection. (A) Representative flow cytometry plots
showing the gating strategy used to identify mDC expressing active caspase-3 (Cas-3). Live mDC were defined as Lineage2 HLA-DR+ CD11c+ cells that
lacked staining with a fixable dead-cell dye. (B) The proportion of lymph node mDC expressing active caspase-3 relative to staining with a control
antibody at intervals before and after SIV infection. Cells were cultured for 3 hours prior to analysis. Shown are mean 6 SEM for naı¨ve (T = 0, n = 14),
progressor (n = 8) and stable n = 10). (C) The proportion of lymph node mDC, taken at 12 weeks post infection from animals with progressive
infection, expressing active caspase-3 after 3 hours in the presence of caspase-8 inhibitor (Cas-8 inh), caspase-9 inhibitor (Cas-9 inh) or control
inhibitor (Control). Boxes represent 25th to 75th percentile and median values, and whiskers represent the minimum and maximum values, using data
from 6 animals. (D) Left: Representative dot plots showing expression of CD95 relative to isotype control antibody to define positively staining cells.
Right: The proportion of lymph node mDC at 12 weeks post infection that express CD95 in naı¨ve animals (n = 4) and animals with progressive (n = 5)
and stable infection (n = 5). Boxes represent 25th to 75th percentile and median values, and whiskers represent minimum and maximum values.
*P,0.05, **P,0.01 between groups; #P,0.05, ##P,0.01, within groups relative to week 0. ART = intervals of antiretroviral therapy.
doi:10.1371/journal.ppat.1001235.g005
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or alternatively that other newly identified costimulatory molecules
from the CD28 and TNFR families not examined here may be
differentially expressed in progressively infected lymph nodes [47].
In our study the two short courses of ART had only modest
although similar effects on virus load in both groups of animals,
reducing virus levels in plasma by ,1.5 logs. This may be due to
the fact that ART was initiated in chronic as opposed to acute
infection and that therapy was limited to PMPA and FTC which
both target the same viral protein, reverse transcriptase. Similarly
limited effects of ART on virus load in SIV infection have been
reported by others [48,49]. Despite this, ART had noticeably
beneficial effects on mDC homeostasis. In blood, ART reduced
mDC activation and transiently restored mDC numbers in
monkeys with progressive infection, consistent with reports in
HIV-infected individuals [8,17,18]. Most strikingly, discontinua-
tion of ART in stable animals led to a marked increase in the
number of mDC in blood. In lymph nodes, ART resulted in a
decrease in mDC apoptosis in animals with progressive infection
and a reduction in mDC responsiveness overall. Consistent with
this finding, expression of proinflammatory factors and CD95L
that likely induce functional activation and apoptosis of mDC are
substantially reduced in SIV- and HIV-infected lymph nodes in
response to ART [19,50,51]. Animals in the progressive infection
group died at a median time of 34 weeks post infection and did not
receive the full second course of ART initiated at week 32. We do
not believe this difference in treatment interval was a determining
factor in survival, as disease status and time to sacrifice were
correlated with virus load at set-point, before initiation of any
therapy, and thus were independent of ART. HIV-infected
individuals with higher baseline virus loads and immune activation
have poorer reconstitution of innate immune cells in response to
ART [16,52]. In our study, differences in baseline virus load
influenced the response to ART, as animals with stable and
progressive infection had transient increases and decreases,
respectively, in the number of blood mDC, although this could
clearly be influenced by the differences in virus load in the two
groups while on ART. It will be important to determine the
impact of improved antiretroviral drug regimens on mDC
dynamics in SIV infection, including the orally available integrase
inhibitors that are highly active in monkeys [53].
Our data indicate that mDC present in lymph nodes in SIV
infected monkeys remain functionally responsive to exogenous
stimulation regardless of disease outcome. The finding that ex vivo
stimulation through TLR8 induced a five-fold increase in
expression of TNF-a relative to naı¨ve animals suggests that these
cells may in fact be hyperresponsive, although testing with a more
extensive panel of agonists targeting different TLR ligands is
needed to confirm this. CCL19 induces terminal activation of DC
and promotes DC production of proinflammatory cytokines within
lymph nodes [54], although this effect would not explain the
finding of increased responsiveness of mDC in animals with stable
infection that had normal levels of CCL19 in our study. It is
possible that other proinflammatory factors such as IFN-c that
induce DC activation [55] and are markedly increased in lymph
nodes during pathogenic SIV infection [56] are responsible for
mDC increased responsiveness in SIV infection.
An increasing emphasis in HIV and SIV pathogenesis is now
placed on the role of gut mucosa in disease, as this is a major site of
Figure 6. Lymph node mDC from SIV infected animals remain responsive to exogenous TLR8 stimulation. The proportion of lymph
node mDC before and after SIV infection that express (A) TNF-a (A) or IL-12 (B) following stimulation with the TLR7/8 agonist 3M-007 for 5 hours.
Shown are mean 6 SEM for naı¨ve (T = 0, n = 13), progressor (n = 7) and stable animals (n = 10). Also shown are representative flow cytometry plots of
the gating strategy to identify positive populations. #P,0.05, ##P,0.01 within groups relative to week 0. ART = interval of antiretroviral therapy.
doi:10.1371/journal.ppat.1001235.g006
Dendritic Cell Dysregulation in SIV Infection
PLoS Pathogens | www.plospathogens.org 10 December 2010 | Volume 6 | Issue 12 | e1001235
virus replication and CD4+ T cell depletion [57–59]. mDC are
recruited to inflamed respiratory mucosal surfaces in children with
respiratory viral infections [60], and it is likely mDC and other DC
subsets are similarly recruited to gut and vaginal mucosa in SIV
infection [61]. It will be important to evaluate the mDC response
in gut mucosa and its relationship to disease progression in SIV
infection. However, such quantitative studies are technically
difficult to perform as the DC is a relatively rare cell that can
only be isolated in sufficient numbers through gut resection
surgeries as opposed to the more commonly performed endoscopic
biopsies.
Collectively, these data suggest that the inflammatory response
associated with increased virus load during progressive SIV
infection leads to an increase in the CCR7-CCL19 chemokine
axis that serves to accelerate mDC recruitment to lymph nodes.
Apoptosis of mDC within tissues during this chronic phase, which
was found only in animals with progressive infection, would
compromise the innate and adaptive immune response to
opportunistic pathogens promoting disease progression. It is
currently not clear whether recently recruited and activated
mDC produce increased levels of proinflammatory cytokines in
vivo that may mediate immune activation characteristic of HIV
and pathogenic SIV infection [62]. Interestingly, increased
turnover of blood monocytes associated with apoptosis of tissue
macrophages has been shown to correlate with progression to
disease in SIV-infected macaques and is a better predictive marker
than viral load or lymphocyte activation [63,64]. This response is
not likely limited to lymph nodes, as evidenced by the fact that
increased monocyte turnover and recruitment to brain correlates
with the severity of SIV encephalitis [65]. These findings point to a
broad-based dysregulation of mDC and monocytes in blood and
tissues as a significant factor in the pathogenesis of AIDS.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee at the University of Pittsburgh (Assurance Number
A3187-01). Surgeries were performed under anesthesia induced
and maintained with ketamine hydrochloride and medetomi-
dine hydrochloride, and all efforts were made to minimize
suffering.
Animal manipulations
Twenty one Indian-origin rhesus macaques (Macaca mulatta)
used in this study were housed at the University of Pittsburgh
Primate Facility for Infectious Disease Research. All animals
were infected by intravenous inoculation with 1,000 TCID50 of
uncloned, pathogenic SIVmac251 (provided by Christopher J.
Miller, California National Primate Research Center). Virus
load in plasma was determined as described previously [66].
ART consisted of PMPA (20 mg/kg/d, subcutaneous injection)
and FTC (30 mg/kg/d, subcutaneous injection; both provided
by Michael Miller, Gilead Sciences) and was given from weeks
12–24 and from weeks 32–44 as described [20]. All animals
except R189 (sacrificed at week 11 post infection) received one or
more administrations of Ad-based vectors during the study
depending on survival. Priming injections of separate Ad5-based
vectors expressing codon-optimized SIVmac239 gag, env and nef
with and without rhesus IL-15.FLAG or empty Ad-y5 were given
by intramuscular injection at week 16 (561010 total viral
particles) and week 22 (161011 total viral particles), and boosting
injections of the same quantity of Ad35-based vectors expressing
the same transgenes were given at week 36 and 42. All Ad vectors
were E1/E3-deleted with the exception of Ad35 containing the
env gene which was E3 deleted. Lymph nodes were taken from
the axillary or inguinal regions prior to infection and at weeks 12,
24 and 32 post infection and single cell suspensions were
generated by disruption and digestion with collagenase D, as
described [67].
Cell identification and enumeration
Identification of mDC was performed as previously described
with some modifications [15,24]. Briefly, PBMC or lymph node
cell suspensions were stained with fluorescently-labeled antibodies
to Lineage markers [CD3 (clone SP34-2; all antibodies from BD
Bioscience unless otherwise noted), CD14 (M5E2), and CD20
(2H7)], HLA-DR (G46-6) and CD11c (S-HCL-3), with and
without antibodies to CD45 (D058-1283), CD80 (L307.4), CD86
(FUN-1), CCR7 (150503, R&D Systems), CD40 (5C3) and CD95
(DX2). An amine-reactive fixable dead-cell dye (Invitrogen) was
used to discriminate live from dead cells. mDC were defined as
Lineage2 HLA-DR+ cells expressing CD11c. In lymph nodes a
broad Lineage2 HLA-DR+/++ gate was used to include all mDC
as described previously The number of blood CD4+ T cells was
quantified using a precise volume of blood stained with antibodies
in the absence of any wash step in TruCOUNT tubes (BD
Biosciences) that contained a known number of fluorescent beads
to provide internal calibration, as previously reported [20]. The
number of blood mDC was then calculated based on the ratio of
mDC to CD4+ T cells in PBMCs at the same time point [24]. All
analyses were done on an LSR II flow cytometer with FACSDiva
software (BD Bioscience).
Cytokine expression and apoptosis
Intracellular cytokine production by lymph node mDC was
measured as described previously for plasmacytoid DC with minor
modifications [38]. Briefly, cell suspensions were cultured for
5 hours with 10 mM of the TLR7/8 agonist 3M-007 (3 M
Pharmaceuticals) with and without the addition of 10 mg/mL
brefeldin A (Sigma) after 1 hour. Cells were stained with surface-
labeling antibodies as above and fixed and permeabilized prior to
incubation with antibody to TNF-a (MAb11) and IL-12 (8.6,
Mitenyi Biotec) and analysis by flow cytometry. To detect
apoptosis in mDC, lymph node cell suspensions were cultured in
media for 3 hours with and without caspase-8 inhibitor Z-IETD-
FMK, caspase-9 inhibitor Z-LEHD-FMK or irrelevant peptide Z-
Fa-FMK (BD Biosciences). Cells were stained with surface-labeling
antibodies as above and fixed and permeabilized prior to
incubation with antibody to active caspase-3 (C92-605) and
analysis by flow cytometry.
Detection of chemokine mRNA expression
Total lymph node RNA was extracted and purified from cell
suspensions generated from biopsies taken prior to or 12 weeks
after infection using the RNAeasy kit (Qiagen) after treatment with
DNAse I (Invitrogen). cDNA was synthesized using random
primers and Superscript II reverse transcriptase (Invitrogen).
Primers and probes from Taqman human gene expression arrays
(Applied Biosystems, Foster City, CA) were utilized for real time
PCR analysis of CCL19, CCL21 and b-glucuronidase expression
as previously described [68]. mRNA expression levels for each
gene were calculated with the 22DCT method using b-glucuron-
idase as the endogenous control [69].
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Statistical analysis
Comparisons between two groups were carried out using the
Mann-Whitney U test. Comparison of DC numbers across
different time points was carried out using the Wilcoxon signed-
rank test. Correlations were determined using the non-parametric
Spearman rank test. Graphpad Prism 5 (Graphpad Software) was
used for statistical analysis. All P values are two-sided with
significance considered to be P,0.05.
Gene identification
The identification of genes analyzed in this paper as defined by
Entrez-Gene are 574386 (CCL19), 574183 (CCL21) and 677692
(b-glucuronidase).
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